These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 28212528)

  • 1. The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia.
    García-Tuñón I; Hernández-Sánchez M; Ordoñez JL; Alonso-Pérez V; Álamo-Quijada M; Benito R; Guerrero C; Hernández-Rivas JM; Sánchez-Martín M
    Oncotarget; 2017 Apr; 8(16):26027-26040. PubMed ID: 28212528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-Cas9 Technology as a Tool to Target Gene Drivers in Cancer: Proof of Concept and New Opportunities to Treat Chronic Myeloid Leukemia.
    Vuelta E; Ordoñez JL; Alonso-Pérez V; Méndez L; Hernández-Carabias P; Saldaña R; Sevilla J; Sebastián E; Muntión S; Sánchez-Guijo F; Hernández-Rivas JM; García-Tuñón I; Sánchez-Martín M
    CRISPR J; 2021 Aug; 4(4):519-535. PubMed ID: 34406033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
    Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic delivery of CRISPR/Cas9 with PEG-PLGA nanoparticles for chronic myeloid leukemia targeted therapy.
    Liu Y; Zhao G; Xu CF; Luo YL; Lu ZD; Wang J
    Biomater Sci; 2018 May; 6(6):1592-1603. PubMed ID: 29725684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient disruption of bcr-abl gene by CRISPR RNA-guided FokI nucleases depresses the oncogenesis of chronic myeloid leukemia cells.
    Luo Z; Gao M; Huang N; Wang X; Yang Z; Yang H; Huang Z; Feng W
    J Exp Clin Cancer Res; 2019 May; 38(1):224. PubMed ID: 31138265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted disruption of the
    Zeng J; Liang X; Duan L; Tan F; Chen L; Qu J; Li J; Li K; Luo D; Hu Z
    Acta Biochim Biophys Sin (Shanghai); 2024 Apr; 56(4):525-537. PubMed ID: 38414349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
    Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
    J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of bcr/abl fusion gene on expression of beta1 integrin and L-selectin in mouse chronic myeloid leukemia cells].
    Wang WL; Shen T; Hui YR; Gu XC; Li RS
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jul; 24(7):337-9. PubMed ID: 12941184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Construction of 293pT2-P210 cell line enables expression of bcr/abl to be regulated by Tet-off inducing-expression-system].
    Huang WR; Lu ZZ; Wang LS; Wang H; Duan HF; Li QF; Gao CJ; DA WM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):224-8. PubMed ID: 17493320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Stable interference on P210(bcr/abl) gene expression by lentiviral vector-delivered shRNA in vitro and in vivo].
    Zhu YF; Wang YZ; Meng FY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1090-4. PubMed ID: 23114125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
    Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
    Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9-Directed Gene Trap Constitutes a Selection System for Corrected
    Vuelta E; Ordoñez JL; Sanz DJ; Ballesteros S; Hernández-Rivas JM; Méndez-Sánchez L; Sánchez-Martín M; García-Tuñón I
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.
    Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Carter BZ; Wang X; Shi X; Liu J
    J Hematol Oncol; 2016 Nov; 9(1):129. PubMed ID: 27884201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine bone marrow transplantation model of CML.
    Ciccarelli BT; Hu T; Wang Q; Kim JJ; Whitehead IP
    Leuk Res; 2020 Oct; 97():106440. PubMed ID: 32892149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is p190 bcr-abl rearrangement necessary for acute transformation in some p210 CML of childhood?
    Scrideli CA; de Oliveira FM; Brassesco MS; de Paula Queiroz R; Bernardes JE; Valera ET; Tone LG
    Leuk Res; 2009 Mar; 33(3):495-9. PubMed ID: 18495245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
    Brusa G; Benvenuti M; Mazzacurati L; Mancini M; Pattacini L; Martinelli G; Barbieri E; Greenberger JS; Baccarani M; Santucci MA
    Haematologica; 2003 Jun; 88(6):622-30. PubMed ID: 12801837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation.
    Sahay S; Pannucci NL; Mahon GM; Rodriguez PL; Megjugorac NJ; Kostenko EV; Ozer HL; Whitehead IP
    Oncogene; 2008 Mar; 27(14):2064-71. PubMed ID: 17922031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.